Gedeon Richter Plc. (“Richter”) today announced that it received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommending that marketing authorization be granted for its biosimilar teriparatide, Terrosa.